Circulating MiR-16-5p and MiR-19b-3p as two novel potential biomarkers to indicate progression of gastric cancer

Theranostics

Volumn 5, Issue 7, 2015, Pages 733-745

  Zhang, Jingpu ^a   Song, Yang ^b   Zhang, Chunlei ^a   Zhi, Xiao ^a   Fu, Hualin ^a,c   Ma, Yue ^a   Chen, Yunsheng ^a   Pan, Fei ^a,c   Wang, Kan ^a   Ni, Jian ^a,c   Jin, Weilin ^a,c   He, Xianli ^b   Su, Haichuan ^b   Cui, Daxiang ^a,c  

^a Shanghai Jiao Tong University   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Circulating microRNA biomarker; Gastric cancer; MiR 16 5p; MiR 19b 3p; MiRNA profiling microarray; Quantitative reverse transcription PCR

Indexed keywords

MICRORNA; MICRORNA 16 5P; MICRORNA 19B 3P; UNCLASSIFIED DRUG; MIRN16 MICRORNA, HUMAN; MIRN19 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GASTRECTOMY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRECANCER; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; STOMACH CANCER; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR;

ADULT; AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 84938699940     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.10305     Document Type: Article

References (52)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010; 127: 2893-2917.
2. Chen WQ, Zheng RS, Zhang SW, et al. Annual report on status of cancer in china, 2010. Chinese J Cancer Res. 2014; 26: 48-58.
3. Hartgrink HH, Jansen EPM, van Grieken NCT, et al. Gastric cancer. The Lancet. 2009; 374: 477-490.
4. Wang J, Yu JC, Kang WM, et al. Treatment strategy for early gastric cancer. Surg Oncol. 2012; 21: 119-123.
5. Taback B, Hoon DSB. Circulating nucleic acids in plasma and serum: past, present and future. Curr Opin Mol Ther. 2004; 6: 273-278.
6. Catalano V, Labianca R, Beretta GD, et al. Gastric cancer. Crit Rev Oncol Hemat. 2009; 71: 127-64.
7. Thiel A, Ristimaki A. Gastric cancer: basic aspects. Helicobacter. 2012; 17: 26-29.
8. Berger F, Reiser MF. MicroRNAs as potential new molecular biomarkers in oncology: have they reached relevance for the clinical imaging sciences? Theranostics. 2013; 3: 943-952.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297.
10. Paulmurugan R. MicroRNAs - a new generation molecular targets for treating cellular diseases. Theranostics. 2013; 3: 927-929.
11. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6: 857-66.
12. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. Embo Mol Med. 2012; 4: 143-159.
13. Kim DN, Chae HS, Oh ST, et al. Expression of viral microRNAs in epstein-barr virus-associated gastric carcinoma. J Virol. 2007; 81: 1033-1036.
14. Mitchell. Circulating microRNAs as stable blood-based markers for cancer detection. P Natl Acad Sci USA. 2008; 105: 10513.
15. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834-838.
16. Srinivasan S, Selvan ST, Archunan G, et al. MicroRNAs -the next generation therapeutic targets in human diseases. Theranostics. 2013; 3: 930-942.
17. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hemat. 2011; 80: 193-208.
18. Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. Brit J Cancer. 2010; 102: 1174-1179.
19. Konishi H, Ichikawa D, Komatsu S, et al. Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Brit J Cancer. 2012; 106: 740-747.
20. Liu R, Zhang CN, Hu ZB, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 2011; 47: 784-791.
21. Liu HS, Zhu L, Liu BY, et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 2012; 316: 196-203.
22. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Th. 2009; 9: 703-711.
23. Mestdagh P, Van Vlierberghe P, De Weer A, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009; 10: R64.
24. McShane LM, Hayes DF. Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol. 2012; 30: 4223-4232.
25. Hermanek P. The superiority of the new international union against cancer and American joint committee on cancer TNM staging of gastric carcinoma. Cancer. 2000; 88: 1763-1765.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods. 2001; 25: 402-408.
27. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29: e45.
28. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA: Cancer J Clin. 2011; 61: 69-90.
29. Bandres E, Bitarte N, Arias F, et al. MicroRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res. 2009; 15: 2281-2290.
30. Kroh EM, Parkin RK, Mitchell PS, et al. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010; 50: 298-301.
31. De Guire V, Robitaille R, Tetreault N, et al. Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: promises and challenges. Clin Biochem. 2013; 46: 846-860.
32. Koshiol J, Wang E, Zhao Y, et al. Strengths and limitations of laboratory procedures for microRNA detection. Cancer Epidem Biomar. 2010; 19: 907-911.
33. Zampetaki A, Mayr M. Analytical challenges and technical limitations in assessing circulating miRNAs. Thromb Haemostasis. 2012; 108: 592-598.
34. Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010; 251: 499-505.
35. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Brit J Haematol. 2008; 141: 672-675.
36. Huang ZH, Huang D, Ni SJA, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010; 127: 118-126.
37. Song J, Bai Z, Han W, et al. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci. 2012; 57: 897-904.
38. McDonald JS, Milosevic D, Reddi HV, et al. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem. 2011; 57: 833-840.
39. Song MY, Pan KF, Su HJ, et al. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One. 2012; 7: e33608.
40. Cai H, Yuan Y, Hao YF, et al. Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol. 2013; 30: 452.
41. Becker N, Lockwood CM. Pre-analytical variables in miRNA analysis. Clin Biochem. 2013; 46: 861-868.
42. Li C, Li JF, Cai Q, et al. MiRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. Ann Surg Oncol. 2013; 20: S397-S405.
43. Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev. 2012; 32: 326-348.
44. Schultz NA, Dehlendorff C, Jensen BV, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. J Am Med Assoc. 2014; 311: 392-404.
45. Mo MH, Chen L, Fu Y, et al. Cell-free circulating miRNA biomarkers in cancer. J Cancer. 2012; 3: 432-448.
46. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006; 25: 6188-6196.
47. Ma QY, Wang XY, Li Z, et al. MicroRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway. Oncol Rep. 2013; 29: 1652-1658.
48. Wu Q, Yang Z, An Y, et al. MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. Cell Death Dis. 2014; 5: e1144.
49. Yang O, Huang JH, Lin S. Regulatory effects of miRNA on gastric cancer cells. Oncol Lett. 2014; 8: 651-656.
50. Ranji N, Sadeghizadeh M, Shokrgozar MA, et al. MiR-17-92 cluster: an apoptosis inducer or proliferation enhancer. Mol Cell Biochem. 2013; 380: 229-238.
51. Tanaka M, Oikawa K, Takanashi M, et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. Plos One. 2009; 4: e5532.
52. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010; 101: 2087-2092.